Top Anti Obesity Drugs Companies

Anti Obesity Drugs Market size was valued at USD 1.9 billion in 2019 and is poised to grow from USD 2.82 billion in 2023 to USD 13.26 billion by 2031, growing at a CAGR of 24.6% in the forecast period (2024-2031).

The top players are concentrated on inorganic expansion tactics such as teaming up with successful individuals and national initiatives or programmes that advertise their goods. As a result, these brands are known earlier than other brands in the industry under investigation. Due to the disease's great prevalence, there is moderate to intense intergroup conflict. 'Novo Nordisk A/S', 'Eisai Co., Ltd.', 'Arena Pharmaceuticals, Inc.', 'F. Hoffmann-La Roche Ltd.', 'Orexigen Therapeutics, Inc.', 'Takeda Pharmaceutical Company Limited', 'Zafgen, Inc.', 'Norgine B.V.', 'GlaxoSmithKline plc', 'Boehringer Ingelheim International GmbH', 'Pfizer Inc.', 'Sanofi S.A.', 'Merck & Co., Inc.', 'VIVUS, Inc.', 'Johnson & Johnson', 'Teva Pharmaceutical Industries Ltd.', 'Bristol-Myers Squibb Company', 'Abbott Laboratories', 'AstraZeneca plc', 'Bayer AG'

Growing worries about appropriate management of obesity have been sparked by the population's significant increase in sufferers. For instance, the World Obesity Federation estimates that 650 million people and 120 million children worldwide are obese at the moment. Additionally, it costs about US$ 2 trillion yearly to manage obesity. Additionally, according to the Centers for Disease Control and Prevention (CDC), 42.5% of US individuals aged 20 and older are obese. The demand for anti-obesity medications is expected to rise during the forecast period due to patients' increased knowledge of the importance of managing weight gain promptly in emerging economies.

The development of various possible therapeutic compounds that target both Type 2 diabetes mellitus and obesity has also become a major trend among companies competing in the anti-obesity industry. The rising prevalence of Type 2 diabetes and obesity is motivating manufacturers and researchers to develop medications that can treat both conditions. Therefore, it is anticipated that the rise in unhealthy eating patterns, sedentary lifestyles, and the obese population will propel market expansion throughout the forecast period.

The North American market has a value of US$ 964.8 million. This region’s dominance can be attributed to the US's strong players and the rising popularity of obesity control products. Due to its efforts in R&D for the creation of therapeutically effective medications, Europe currently occupies the second-place position in the market. Growth is anticipated during the projection period as a result of this as well as rising public awareness of the advantages of weight loss.

Global Anti Obesity Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 30.26 billion by 2032, growing at a CAGR of 26.3% during the forecast period (2025-2032).

The top players are concentrated on inorganic expansion tactics such as teaming up with successful individuals and national initiatives or programmes that advertise their goods. As a result, these brands are known earlier than other brands in the industry under investigation. Due to the disease's great prevalence, there is moderate to intense intergroup conflict. 'Novo Nordisk A/S (Denmark) ', 'Eli Lilly and Company (USA) ', 'Roche Holding AG (Switzerland) ', 'Pfizer Inc. (USA) ', 'Currax Pharmaceuticals LLC (USA) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Amgen Inc. (USA) ', 'AstraZeneca PLC (UK/Sweden) ', 'GlaxoSmithKline plc (UK) ', 'Sanofi S.A. (France) ', 'Rhythm Pharmaceuticals, Inc. (USA) ', 'Gelesis Holdings, Inc. (USA) ', 'Merck & Co., Inc. (USA) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Eisai Co., Ltd. (Japan) ', 'Orexigen Therapeutics, Inc. (USA) ', 'Zafgen Inc. (USA) (Ceased operations) ', 'VIVUS LLC (USA) (Acquired by Currax Pharmaceuticals) ', 'Cheplapharm Arzneimittel GmbH (Germany) ', 'KVK Tech Inc. (USA)'

Growing worries about appropriate management of obesity have been sparked by the population's significant increase in sufferers. For instance, the World Obesity Federation estimates that 650 million people and 120 million children worldwide are obese at the moment. Additionally, it costs about US$ 2 trillion yearly to manage obesity. Additionally, according to the Centers for Disease Control and Prevention (CDC), 42.5% of US individuals aged 20 and older are obese. The demand for anti-obesity medications is expected to rise during the forecast period due to patients' increased knowledge of the importance of managing weight gain promptly in emerging economies.

The development of various possible therapeutic compounds that target both Type 2 diabetes mellitus and obesity has also become a major trend among companies competing in the anti-obesity industry. The rising prevalence of Type 2 diabetes and obesity is motivating manufacturers and researchers to develop medications that can treat both conditions. Therefore, it is anticipated that the rise in unhealthy eating patterns, sedentary lifestyles, and the obese population will propel market expansion throughout the forecast period.

The North American market has a value of US$ 964.8 million. This region’s dominance can be attributed to the US's strong players and the rising popularity of obesity control products. Due to its efforts in R&D for the creation of therapeutically effective medications, Europe currently occupies the second-place position in the market. Growth is anticipated during the projection period as a result of this as well as rising public awareness of the advantages of weight loss.